Skip to main content

Table 3 Comparison to women using lithium prior to pregnancy but not during

From: Maternal lithium use and the risk of adverse pregnancy and neonatal outcomes: a Swedish population-based cohort study

 

Lithium prior

n=871

Lithium during

n=434

 

n (%)

n (%)

Relative risk (95% confidence interval)

Crude

Adjusted

Primary outcomes

 Preeclampsia

33 (3.8)

15 (3.5)

0.91 (0.50, 1.67)

0.86 (0.44, 1.70)

 Spontaneous preterm birth

37 (4.4)

36 (8.7)

1.95 (1.23, 3.09)

2.08 (1.20, 3.59)

 Small for gestational age

31 (3.6)

13 (3.0)

0.84 (0.42, 1.70)

0.91 (0.42, 2.01)

 Large for gestational age

37 (4.3)

39 (9.0)

2.12 (1.37, 3.28)

1.86 (1.10, 3.13)

Secondary outcomes

 Macrosomia

138 (15.8)

93 (21.4)

0.67 (0.14, 3.30)

0.50 (0.09, 2.68)

 Hypoglycaemia

23 (2.6)

24 (5.5)

2.09 (1.20, 3.66)

2.72 (1.47, 5.04)

 Five-minute Apgar < 6

16 (1.9)

11 (2.5)

1.37 (0.62, 3.04)

2.25 (0.89, 5.66)

 Malformations (all)

25 (2.9)

19 (4.4)

1.52 (0.85, 2.73)

1.47 (0.77, 2.80)

 Cardiac malformations

7 (0.8)

9 (2.1)

2.58 (0.97, 6.86)

2.99 (1.10, 8.10)_

 Perinatal death

3 (0.3)

2 (0.5)

2.68 (0.45, 15.90)

2.26 (0.21, 24.54)

  1. Adjusted analyses were retrieved via inverse probability weighting with maternal age, body mass index, smoking status, country of birth, education, parity and medical conditions, and the use of antipsychotics, neuroleptics and lamotrigine during pregnancy were included as covariates